Izotropic Corporation

Commercializing a Dedicated Breast CT Platform for the Earlier Detection, Diagnosis and Treatment of Breast Cancers

Recent News

  • Alexander Tokman Joins Izotropic Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - November 11, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that Advisor Mr. Alexander Tokman has joined the Company's Board of Directors. Strengthening the Board of Directors with strategic and well-connected industry executives is pertinent to effectively implementing the Company's short and long-term...

    2022-11-11 8:00 AM EST
  • Izotropic's IzoView Is Weeks Away from Final Engineering & Showcasing to Investment and Scientific Communities

    Vancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that the engineering and construction of IzoView is weeks away from completion and subsequent unveiling to existing shareholders, and the investment, medical and scientific communities.Full assembly of IzoView is approximately four weeks from completion, and the imaging subsystem...

    2022-10-25 8:00 AM EDT
  • Izotropic Finalizes Engineering and Development Transition to the United States; Establishes Operations in Primary Target Market

    Vancouver, British Columbia--(Newsfile Corp. - August 11, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a MedTech company commercializing IzoView, an advanced three-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer, is pleased to report the Company has successfully relocated IzoView and associated components and completed the transition of all major medical device engineering and product development operations to California.Further to the Company's prior...

    2022-08-11 8:00 AM EDT
  • Izotropic Engages Clinical Research Organization in Preparation for Clinical Study

    Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a MedTech company commercializing IzoView, an advanced breast CT (computed tomography) imaging platform for the more accurate detection and diagnosis of breast cancer, announces it has engaged a world-leading clinical research organization (CRO) ICON plc ("ICON") to help prepare for its upcoming clinical study and submission for market authorization in the U.S.With over 20 years of experience and having...

    2022-07-19 8:00 AM EDT
  • Izotropic Reacts to Supply Chain Disruptions and Updates IzoView Engineering Timelines

    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announces timeline updates for the initial IzoView commercial prototype build. Supply chain issues and unforeseen impacts on engineering work have resulted in an estimated delay of up to 3 quarters to the Company's previously projected timelines.Engineering...

    2022-06-29 9:00 AM EDT
  • Izotropic stellt kommerziellen IzoView-Prototyp vor und reicht neue Patente ein

    Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 12. Mai 2022) - Die Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen"), ein Unternehmen, das seine Brust-CT (Computertomographie)-Bildgebungsplattform IzoView für die genauere Brustkrebserkennung und -diagnose kommerzialisiert, freut sich, das kommerzielle Prototyp-Gerätedesign vorzustellen, das in bevorstehenden klinischen Studien zur Marktzulassung in den USA eingesetzt wird.

    2022-05-12 4:53 PM EDT
  • Izotropic Unveils Izoview Commercial Prototype, Files New Patents

    Vancouver, British Columbia--(Newsfile Corp. - May 10, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, is pleased to unveil the commercial prototype device design that will be used in forthcoming clinical studies for market authorization in the U.S.

    2022-05-10 8:00 AM EDT
  • Izotropic Corporation Announces Closing of Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - April 4, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, is pleased to announce, further to its news release on March 30, 2022, that it has completed a non-brokered private placement (the "Offering") of unsecured promissory notes (each, a "Note") pursuant to which the Company issued: (i) Notes purchased for an aggregate...

    2022-04-04 8:00 AM EDT